Interferon alpha-2b controlled-release - Avadel Pharmaceuticals

Drug Profile

Interferon alpha-2b controlled-release - Avadel Pharmaceuticals

Alternative Names: IFN alfa-2b XL; IFN alpha-2b XL; IFN-α XL; Interferon alfa-2b XL; Interferon alpha-2b XL; Interferon alpha-2b XL - Avadel Pharmaceuticals; Long-acting IFN-α XL; Long-acting interferon alpha-2b

Latest Information Update: 15 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Flamel Technologies
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 23 Oct 2012 Interferon alpha-2b controlled-release - Flamel Technologies is available for licensing \http://www.flamel.com/\
  • 18 Oct 2011 Interferon alpha-2b (controlled-release) is still in phase IIa trials for Hepatitis C in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top